MDxHealth is trading 5.16% down at $0.75 after opening-day weakness on August 26, 2026; no reliable catalyst was identified.
- The latest company disclosure remains the August 13 second-quarter report, which showed $27.2 million in revenue.
- The company’s 2026 guidance remains $110–$115 million.
- Broader markets are only modestly lower and do not clearly explain the move.